In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...
Read MoreOngoing treatment(s)-Biological therapy Posts on Medivizor
Stopping TKI treatment in chronic myeloid leukemia
In a nutshell This study was an update on the guidelines of stopping tyrosine kinase inhibitor (TKI) therapy in the treatment of chronic myeloid leukemia (CML). New guidelines confirm the safety of stopping TKI therapy in patients with CML. Some background Chronic myeloid leukemia is often treated with TKI therapy. These are drugs which...
Read MoreLooking for patients with lung cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial is examining the effectiveness of durvalumab (Imfinzi) and monalizumab to treat patients with solid tumors, including lung cancer. The main outcomes to be measured are tumor response to the treatment and side effects. The details Cancer is one of the leading causes of death worldwide. Chemotherapy is only of limited...
Read MoreRate of deep molecular response in chronic myeloid leukemia treated with nilotinib
In a nutshell This study aimed to investigate the rate of deep molecular response in patients with newly diagnosed chronic myeloid leukemia who were treated with nilotinib. This study concluded that good molecular response rates are seen in these patients. Some background Molecular response (MR) is a measure of the levels of BCR-ABL1 gene in leukemia...
Read MoreEffectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia
In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...
Read MoreCan monitoring minimal residual disease levels in CLL predict outcomes?
In a nutshell This study assessed if monitoring the minimal residual disease (MRD) levels in chronic lymphocytic leukemia (CLL) can help guide future treatment strategies. This study concluded MRD monitoring can be used to predict outcomes and may help guide future treatment choices. Some background Chronic lymphocytic leukemia is a cancer of...
Read MoreIs reducing the dose of imatinib effective in the treatment of chronic myeloid leukemia?
In a nutshell This study looked at the effectiveness of reducing the dose of imatinib (Gleevec) in the treatment of chronic myeloid leukemia (CML). Researchers found that a lower dose of imatinib can achieve the same result as a high dose in most patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to...
Read MoreCan molecular monitoring help treatment and outcomes in patients with chronic myeloid leukemia?
In a nutshell This study looked at the use of molecular monitoring to assess outcomes in patients with chronic myeloid leukemia. Researchers found that molecular monitoring at 3 and 12 months is beneficial to these patients. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This leads to an abnormal immune system and...
Read MoreEvaluating the safety of ibrutinib in leukemia and lymphoma
In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...
Read MoreCyroablation for the treatment of early stage prostate cancer
In a nutshell This study evaluated the long-term safety and effectiveness of cryoablation (a process that uses extreme cold to destroy tissue) for patients with early prostate cancer. This study found that cryoablation is safe and effective for early-stage prostate cancer. Some background Cryoablation is a treatment option for early-stage prostate...
Read MorePonatinib as a second-line treatment for chronic-phase chronic myeloid leukemia
In a nutshell This study aimed to investigate if ponatinib is a suitable second-line treatment option for patients with chronic-phase chronic myeloid leukemia. This study concluded that ponatinib is a suitable option for these patients. Some background Ponatinib (Iclusig) is a tyrosine kinase inhibitor (TKI). TKIs work by blocking proteins...
Read MoreCAR-T cell therapy and infection risk
In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies. Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...
Read More
